Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
Aquestive Therapeutics (AQST) PT Lowered to $21 at BMO Capital
March 15, 2019 6:51 AM EDTBMO Capital analyst Gary Nachman lowered the price target on Aquestive Therapeutics (NASDAQ: AQST) to $21.00 (from $24.00) while maintaining a Outperform rating following relatively in-line 4Q18 results.
guidance is appropriately conservative and should be very achievablemanagement sounded confident in several potential nondilutive financing options... More
Aquestive Therapeutics Inc. (AQST) Misses Q4 EPS by 5c, Revenues Beat; Offers FY19 Revenue Below Guidance
March 14, 2019 7:12 AM EDTAquestive Therapeutics Inc. (NASDAQ: AQST) reported Q4 EPS of ($0.56), $0.05 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $16.69 million.
"Aquestive made significant progress in 2018 by launching our first proprietary product and continuing our transformation into a... More
